SCHEMBL2687136

SCHEMBL2687136

O=C(O)NC(Cc1ccccc1)C(=O)N1CCc2ccc(-c3ccncc3)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 5/20 0.50
NPSR1 Q6W5P4 2/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 1/20 0.44
TSHR P16473 1/20 0.43
GPR142 Q7Z601 1/20 0.43
FPR1 P21462 4/20 0.43
KMT2A Q03164 1/20 0.42
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42
CTSS P25774 1/20 0.42
ROCK2 O75116 3/20 0.42
ROCK1 Q13464 3/20 0.42
RPS6KA5 O75582 2/20 0.42
RPS6KA4 O75676 2/20 0.42
PRKACA P17612 2/20 0.42
MAPK1 P28482 2/20 0.42
GSK3B P49841 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685377 0.89 FPR2 (0.49) FPR2NPSR1GAAMAPTCYP11B1
SCHEMBL2685129 0.89 FPR2 (0.54) FPR2NPSR1GAAMAPTTSHR
SCHEMBL5960587 0.87 SCN9A (0.48) FPR2NPSR1GAAMAPTKMT2A
SCHEMBL3793422 0.85 EP300 (0.49) FPR2NPSR1GAAMAPTTSHR
SCHEMBL2685052 0.85 EP300 (0.49) FPR2NPSR1GAAMAPTTSHR
SCHEMBL2685606 0.85 HDAC8 (0.47) NPSR1GAAMAPTCYP11B1CYP11B2
SCHEMBL2685605 0.85 HDAC8 (0.47) NPSR1GAAMAPTCYP11B1CYP11B2
SCHEMBL2685114 0.84 GPR142 (0.51) FPR2NPSR1GAAMAPTCYP11B1
SCHEMBL2685108 0.84 GPR142 (0.51) FPR2NPSR1GAAMAPTCYP11B1
SCHEMBL2684655 0.82 FPR2 (0.65) FPR2NPSR1GAAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A FPR2 1040/4885NPSR1 850/4885GAA 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.